Tocagen exists for you, the patient. You drive us to pursue the discovery, development and commercialization of novel products that treat cancer, with an initial focus on advanced cancers for which there are no adequate therapies today.

Our cancer-selective gene therapy platform is designed to safely and selectively provide long-term presence of a therapeutic gene which activates your immune system against the cancer from within. View our scientific publications.

Phase 1 clinical trials of our lead investigational product, Toca 511 & Toca FC, have shown potential benefits, including durable objective responses, extended overall survival and a favorable safety profile. But this is just the beginning. We plan to develop additional product candidates that are designed to activate the patient’s immune system against their own cancer from within.

Also, we are planning to evaluate Toca 511 & Toca FC in patients with newly diagnosed glioblastoma. We will collaborate on this trial with the National Cancer Institute’s NRG Oncology. In addition, we plan to initiate a clinical trial of the regimen in patients with non-muscle invasive bladder cancer (NMIBC).

Toca 511 & Toca FC are investigational products. An investigational product is one that has not been proven to be safe and effective and is not licensed by the U.S. Food and Drug Administration or any other government agency. An investigational product can only be administered in a research study.